HAYWARD, Calif., Jan. 7, 2020 /PRNewswire/ -- Paragon Genomics, Inc., a leader in amplicon-based target enrichment solutions for next-generation sequencing (NGS) and precision medicine, today announced that it will present at Biotech Showcase™ 2020, to be held January 13–15, 2020 at the Hilton San Francisco Union Square. Paragon Genomics CEO Tao Chen will give a corporate presentation and meet with investors.
Date: Tuesday, January 14, 2020
Presentation Time: 1:45 pm PST
Room: Yosemite C (Ballroom Level)
Tao Chen commented, "During the past year Paragon Genomics launched important new products for our growing customer base and recorded substantial growth in product sales in both the U.S. and China. Our CleanPlex® technology has the potential to make NGS-based genomic analyses across a wide variety of applications faster, easier, more accurate, more economical and more feasible. Our clients have successfully applied our technologies to applications such as tumor profiling, inherited disease testing, reproductive health, drug discovery, single cell analysis and agrigenomics. We anticipate robust expansion in 2020 and look forward to sharing our exciting story with early stage life science investors in San Francisco next week."
Paragon Genomics' CleanPlex is a proprietary, ultra-high multiplexed NGS target enrichment technology featuring an innovative PCR background cleaning chemistry that allows tens of thousands of amplicons to be multiplexed in a single reaction pool, allowing a large number of targets to be interrogated in a single assay. The CleanPlex technology is available as ready-to-use panels or as customized assays designed and optimized using the company's advanced panel design algorithm.
Investors interested in scheduling a meeting with Paragon Genomics leadership in San Francisco should contact investment@paragongenomics.com. Investors interested in attending Biotech Showcase can visit informaconnect.com/biotech-showcase/ for more information.
About Paragon Genomics
Paragon Genomics (paragongenomics.com) is a leader in amplicon-based target enrichment and library preparation solutions to accelerate the development of next-generation sequencing (NGS)-based assays for research and clinical testing. The company designs and manufactures high performance and ultra-multiplexed amplicon NGS library preparation products for analyzing difficult, clinically relevant samples. It strives to be the NGS assay partner of choice for research and clinical NGS labs and make custom NGS assays easily available to a broad range of users. Privately held Paragon Genomics is located in Hayward, California.
Contacts:
Corporate: | Media: |
Paragon Genomics | Barbara Lindheim |
Tao Chen | BLL Partners for Paragon Genomics |
CEO | |
(917) 355-9234 |
SOURCE Paragon Genomics, Inc.
